The prevention of colorectal cancer

Colorectal cancer is a leading cause of cancer mortality in the industrialized world. Survival remains poor because most cases are diagnosed at an advanced stage. It is a preventable disease as colorectal cancers usually develop slowly from an identifiable precursor lesion, the adenoma.The existing strategies for colorectal cancer prevention include dietary prevention, chemoprevention and endoscopic intervention. The exact relationship between diet, particularly fibre, and colorectal cancer remains unclear, with the most recent studies suggesting that dietary fibre may not decrease colorectal cancer risk as previously thought.Non‐steroidal anti‐inflammatory drugs have been shown to have a protective effect against colorectal cancer, but the adverse effect profile of the non COX‐2 selective drugs, particularly the risk of gastrointestinal haemorrhage, precludes their widespread use.There is increasing evidence that colorectal cancer incidence and mortality can be decreased from endoscopic polypectomy and early detection of cancer. Faecal occult blood testing in the general population (‘average‐risk’) has been shown in randomized trials to decrease mortality from colorectal cancer by 15–33%. Long‐term results of randomized trials of the effectiveness of flexible sigmoidoscopy and colonoscopy screening in the general population are awaited.Targeting high risk individuals may also be an effective and efficient way to decrease the colorectal cancer burden. As many as 15–30% of colorectal cases may be due to hereditary factors. Individuals with one or two direct relatives affected are at moderate risk for colorectal cancer (empirical lifetime mortality from colorectal cancer approximately 10%) and approximately 2–3% of cases arise in individuals harbouring highly penetrant autosomal dominant mutations, which puts them at high‐risk for colorectal cancer. Surveillance colonoscopy is offered to individuals at moderate and high risk for colorectal cancer.